Fluorouracil (5FU) Comprehensive Study by Type (Injection Product, Tablets Product, Oral Solution Product), Application (Breast Cancer, Head and Neck Cancers, Anal Cancer, Stomach Cancer, Colon Cancer, Skin Cancers), End User (Hospitals, Clinics, Cancer Research Institutes) Players and Region - Global Market Outlook to 2024

Fluorouracil (5FU) Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Fluorouracil is also called as FU or 5FU and is one of the most commonly used drugs to treat cancer. It is part of a group of chemotherapy drugs known as anti-metabolites. Anti-metabolites are like normal body molecules but they have a slightly different structure. Fluorouracil (5FU) can cause side effects but these can affect everyone differently such as increased risk of infection, Anaemia (low level of red blood cells), Nosebleeds, Loss of appetite and other. Rising incidence and prevalence of various cancer types and growing concerns over high death rates due to cancer are the major factors boosting the global fluorouracil (5FU) marketThis growth is primarily driven by Rising incidence and prevalence of various cancer types and Rise in need for R&D activities in cancer.

Globally, a noticeable market trend is evident Growing concerns over high death rates due to cancer. The Pharmaceuticals sector in the North America region has been increasing at a strong rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as NPS MedicineWise (Australia), Taj Pharmaceuticals Limited (India), Celon Labs (India), Shree Ganesh Rubber & Chemicals Co (India), Mylan N.V. (United States), Chandra Bhagat Pharma Pvt. Ltd. (India), Neon Laboratories Ltd (India), Mayne Pharma (Australia), Glaxo Smithkline Pharmaceuticals Ltd. (India) and Dabur Pharmaceuticals Ltd. (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 23 July, 2018, Mayne Pharma today announce that it has completed the acquisition of generic Efudex (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc.

Market Drivers
  • Rising incidence and prevalence of various cancer types
  • Rise in need for R&D activities in cancer

Market Trend
  • Growing concerns over high death rates due to cancer

Restraints
  • Adverse effects of anti-cancer drugs

Opportunities
Advancement of anti-cancer drugs research
Challenges
High cost of drug development and threat of failure

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Injection Product
  • Tablets Product
  • Oral Solution Product
By Application
  • Breast Cancer
  • Head and Neck Cancers
  • Anal Cancer
  • Stomach Cancer
  • Colon Cancer
  • Skin Cancers
By End User
  • Hospitals
  • Clinics
  • Cancer Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising incidence and prevalence of various cancer types
      • 3.2.2. Rise in need for R&D activities in cancer
    • 3.3. Market Challenges
      • 3.3.1. High cost of drug development and threat of failure
    • 3.4. Market Trends
      • 3.4.1. Growing concerns over high death rates due to cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fluorouracil (5FU), by Type, Application, End User and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Fluorouracil (5FU) (Value)
      • 5.2.1. Global Fluorouracil (5FU) by: Type (Value)
        • 5.2.1.1. Injection Product
        • 5.2.1.2. Tablets Product
        • 5.2.1.3. Oral Solution Product
      • 5.2.2. Global Fluorouracil (5FU) by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Head and Neck Cancers
        • 5.2.2.3. Anal Cancer
        • 5.2.2.4. Stomach Cancer
        • 5.2.2.5. Colon Cancer
        • 5.2.2.6. Skin Cancers
      • 5.2.3. Global Fluorouracil (5FU) by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Cancer Research Institutes
      • 5.2.4. Global Fluorouracil (5FU) Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Fluorouracil (5FU) (Price)
      • 5.3.1. Global Fluorouracil (5FU) by: Type (Price)
  • 6. Fluorouracil (5FU): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. NPS MedicineWise (Australia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Taj Pharmaceuticals Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celon Labs (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Shree Ganesh Rubber & Chemicals Co (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan N.V. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chandra Bhagat Pharma Pvt. Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neon Laboratories Ltd (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mayne Pharma (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Glaxo Smithkline Pharmaceuticals Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dabur Pharmaceuticals Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Fluorouracil (5FU) Sale, by Type, Application, End User and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Fluorouracil (5FU) (Value)
      • 7.2.1. Global Fluorouracil (5FU) by: Type (Value)
        • 7.2.1.1. Injection Product
        • 7.2.1.2. Tablets Product
        • 7.2.1.3. Oral Solution Product
      • 7.2.2. Global Fluorouracil (5FU) by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Head and Neck Cancers
        • 7.2.2.3. Anal Cancer
        • 7.2.2.4. Stomach Cancer
        • 7.2.2.5. Colon Cancer
        • 7.2.2.6. Skin Cancers
      • 7.2.3. Global Fluorouracil (5FU) by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Cancer Research Institutes
      • 7.2.4. Global Fluorouracil (5FU) Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Fluorouracil (5FU) (Price)
      • 7.3.1. Global Fluorouracil (5FU) by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fluorouracil (5FU): by Type(USD Million)
  • Table 2. Fluorouracil (5FU) Injection Product , by Region USD Million (2013-2018)
  • Table 3. Fluorouracil (5FU) Tablets Product , by Region USD Million (2013-2018)
  • Table 4. Fluorouracil (5FU) Oral Solution Product , by Region USD Million (2013-2018)
  • Table 5. Fluorouracil (5FU): by Application(USD Million)
  • Table 6. Fluorouracil (5FU) Breast Cancer , by Region USD Million (2013-2018)
  • Table 7. Fluorouracil (5FU) Head and Neck Cancers , by Region USD Million (2013-2018)
  • Table 8. Fluorouracil (5FU) Anal Cancer , by Region USD Million (2013-2018)
  • Table 9. Fluorouracil (5FU) Stomach Cancer , by Region USD Million (2013-2018)
  • Table 10. Fluorouracil (5FU) Colon Cancer , by Region USD Million (2013-2018)
  • Table 11. Fluorouracil (5FU) Skin Cancers , by Region USD Million (2013-2018)
  • Table 12. Fluorouracil (5FU): by End User(USD Million)
  • Table 13. Fluorouracil (5FU) Hospitals , by Region USD Million (2013-2018)
  • Table 14. Fluorouracil (5FU) Clinics , by Region USD Million (2013-2018)
  • Table 15. Fluorouracil (5FU) Cancer Research Institutes , by Region USD Million (2013-2018)
  • Table 16. South America Fluorouracil (5FU), by Country USD Million (2013-2018)
  • Table 17. South America Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 18. South America Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 19. South America Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 20. Brazil Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 21. Brazil Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 22. Brazil Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 23. Argentina Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 24. Argentina Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 25. Argentina Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 26. Rest of South America Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 27. Rest of South America Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 28. Rest of South America Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 29. Asia Pacific Fluorouracil (5FU), by Country USD Million (2013-2018)
  • Table 30. Asia Pacific Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 31. Asia Pacific Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 32. Asia Pacific Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 33. China Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 34. China Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 35. China Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 36. Japan Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 37. Japan Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 38. Japan Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 39. India Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 40. India Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 41. India Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 42. South Korea Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 43. South Korea Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 44. South Korea Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 45. Taiwan Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 46. Taiwan Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 47. Taiwan Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 48. Australia Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 49. Australia Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 50. Australia Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 53. Rest of Asia-Pacific Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 54. Europe Fluorouracil (5FU), by Country USD Million (2013-2018)
  • Table 55. Europe Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 56. Europe Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 57. Europe Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 58. Germany Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 59. Germany Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 60. Germany Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 61. France Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 62. France Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 63. France Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 64. Italy Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 65. Italy Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 66. Italy Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 67. United Kingdom Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 68. United Kingdom Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 69. United Kingdom Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 70. Netherlands Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 71. Netherlands Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 72. Netherlands Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 73. Rest of Europe Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 74. Rest of Europe Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 75. Rest of Europe Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 76. MEA Fluorouracil (5FU), by Country USD Million (2013-2018)
  • Table 77. MEA Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 78. MEA Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 79. MEA Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 80. Middle East Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 81. Middle East Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 82. Middle East Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 83. Africa Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 84. Africa Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 85. Africa Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 86. North America Fluorouracil (5FU), by Country USD Million (2013-2018)
  • Table 87. North America Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 88. North America Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 89. North America Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 90. United States Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 91. United States Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 92. United States Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 93. Canada Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 94. Canada Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 95. Canada Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 96. Mexico Fluorouracil (5FU), by Type USD Million (2013-2018)
  • Table 97. Mexico Fluorouracil (5FU), by Application USD Million (2013-2018)
  • Table 98. Mexico Fluorouracil (5FU), by End User USD Million (2013-2018)
  • Table 99. Fluorouracil (5FU): by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Fluorouracil (5FU): by Type(USD Million)
  • Table 111. Fluorouracil (5FU) Injection Product , by Region USD Million (2019-2024)
  • Table 112. Fluorouracil (5FU) Tablets Product , by Region USD Million (2019-2024)
  • Table 113. Fluorouracil (5FU) Oral Solution Product , by Region USD Million (2019-2024)
  • Table 114. Fluorouracil (5FU): by Application(USD Million)
  • Table 115. Fluorouracil (5FU) Breast Cancer , by Region USD Million (2019-2024)
  • Table 116. Fluorouracil (5FU) Head and Neck Cancers , by Region USD Million (2019-2024)
  • Table 117. Fluorouracil (5FU) Anal Cancer , by Region USD Million (2019-2024)
  • Table 118. Fluorouracil (5FU) Stomach Cancer , by Region USD Million (2019-2024)
  • Table 119. Fluorouracil (5FU) Colon Cancer , by Region USD Million (2019-2024)
  • Table 120. Fluorouracil (5FU) Skin Cancers , by Region USD Million (2019-2024)
  • Table 121. Fluorouracil (5FU): by End User(USD Million)
  • Table 122. Fluorouracil (5FU) Hospitals , by Region USD Million (2019-2024)
  • Table 123. Fluorouracil (5FU) Clinics , by Region USD Million (2019-2024)
  • Table 124. Fluorouracil (5FU) Cancer Research Institutes , by Region USD Million (2019-2024)
  • Table 125. South America Fluorouracil (5FU), by Country USD Million (2019-2024)
  • Table 126. South America Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 127. South America Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 128. South America Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 129. Brazil Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 130. Brazil Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 131. Brazil Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 132. Argentina Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 133. Argentina Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 134. Argentina Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 135. Rest of South America Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 136. Rest of South America Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 137. Rest of South America Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 138. Asia Pacific Fluorouracil (5FU), by Country USD Million (2019-2024)
  • Table 139. Asia Pacific Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 140. Asia Pacific Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 141. Asia Pacific Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 142. China Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 143. China Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 144. China Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 145. Japan Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 146. Japan Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 147. Japan Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 148. India Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 149. India Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 150. India Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 151. South Korea Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 152. South Korea Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 153. South Korea Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 154. Taiwan Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 155. Taiwan Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 156. Taiwan Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 157. Australia Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 158. Australia Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 159. Australia Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 160. Rest of Asia-Pacific Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 161. Rest of Asia-Pacific Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 162. Rest of Asia-Pacific Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 163. Europe Fluorouracil (5FU), by Country USD Million (2019-2024)
  • Table 164. Europe Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 165. Europe Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 166. Europe Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 167. Germany Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 168. Germany Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 169. Germany Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 170. France Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 171. France Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 172. France Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 173. Italy Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 174. Italy Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 175. Italy Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 176. United Kingdom Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 177. United Kingdom Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 178. United Kingdom Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 179. Netherlands Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 180. Netherlands Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 181. Netherlands Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 182. Rest of Europe Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 183. Rest of Europe Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 184. Rest of Europe Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 185. MEA Fluorouracil (5FU), by Country USD Million (2019-2024)
  • Table 186. MEA Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 187. MEA Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 188. MEA Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 189. Middle East Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 190. Middle East Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 191. Middle East Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 192. Africa Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 193. Africa Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 194. Africa Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 195. North America Fluorouracil (5FU), by Country USD Million (2019-2024)
  • Table 196. North America Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 197. North America Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 198. North America Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 199. United States Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 200. United States Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 201. United States Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 202. Canada Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 203. Canada Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 204. Canada Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 205. Mexico Fluorouracil (5FU), by Type USD Million (2019-2024)
  • Table 206. Mexico Fluorouracil (5FU), by Application USD Million (2019-2024)
  • Table 207. Mexico Fluorouracil (5FU), by End User USD Million (2019-2024)
  • Table 208. Fluorouracil (5FU): by Type(USD/Units)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fluorouracil (5FU): by Type USD Million (2013-2018)
  • Figure 5. Global Fluorouracil (5FU): by Application USD Million (2013-2018)
  • Figure 6. Global Fluorouracil (5FU): by End User USD Million (2013-2018)
  • Figure 7. South America Fluorouracil (5FU) Share (%), by Country
  • Figure 8. Asia Pacific Fluorouracil (5FU) Share (%), by Country
  • Figure 9. Europe Fluorouracil (5FU) Share (%), by Country
  • Figure 10. MEA Fluorouracil (5FU) Share (%), by Country
  • Figure 11. North America Fluorouracil (5FU) Share (%), by Country
  • Figure 12. Global Fluorouracil (5FU): by Type USD/Units (2013-2018)
  • Figure 13. Global Fluorouracil (5FU) share by Players 2018 (%)
  • Figure 14. Global Fluorouracil (5FU) share by Players (Top 3) 2018(%)
  • Figure 15. Global Fluorouracil (5FU) share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. NPS MedicineWise (Australia) Revenue, Net Income and Gross profit
  • Figure 18. NPS MedicineWise (Australia) Revenue: by Geography 2018
  • Figure 19. Taj Pharmaceuticals Limited (India) Revenue, Net Income and Gross profit
  • Figure 20. Taj Pharmaceuticals Limited (India) Revenue: by Geography 2018
  • Figure 21. Celon Labs (India) Revenue, Net Income and Gross profit
  • Figure 22. Celon Labs (India) Revenue: by Geography 2018
  • Figure 23. Shree Ganesh Rubber & Chemicals Co (India) Revenue, Net Income and Gross profit
  • Figure 24. Shree Ganesh Rubber & Chemicals Co (India) Revenue: by Geography 2018
  • Figure 25. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Mylan N.V. (United States) Revenue: by Geography 2018
  • Figure 27. Chandra Bhagat Pharma Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 28. Chandra Bhagat Pharma Pvt. Ltd. (India) Revenue: by Geography 2018
  • Figure 29. Neon Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 30. Neon Laboratories Ltd (India) Revenue: by Geography 2018
  • Figure 31. Mayne Pharma (Australia) Revenue, Net Income and Gross profit
  • Figure 32. Mayne Pharma (Australia) Revenue: by Geography 2018
  • Figure 33. Glaxo Smithkline Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 34. Glaxo Smithkline Pharmaceuticals Ltd. (India) Revenue: by Geography 2018
  • Figure 35. Dabur Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 36. Dabur Pharmaceuticals Ltd. (India) Revenue: by Geography 2018
  • Figure 37. Global Fluorouracil (5FU): by Type USD Million (2019-2024)
  • Figure 38. Global Fluorouracil (5FU): by Application USD Million (2019-2024)
  • Figure 39. Global Fluorouracil (5FU): by End User USD Million (2019-2024)
  • Figure 40. South America Fluorouracil (5FU) Share (%), by Country
  • Figure 41. Asia Pacific Fluorouracil (5FU) Share (%), by Country
  • Figure 42. Europe Fluorouracil (5FU) Share (%), by Country
  • Figure 43. MEA Fluorouracil (5FU) Share (%), by Country
  • Figure 44. North America Fluorouracil (5FU) Share (%), by Country
  • Figure 45. Global Fluorouracil (5FU): by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • NPS MedicineWise (Australia)
  • Taj Pharmaceuticals Limited (India)
  • Celon Labs (India)
  • Shree Ganesh Rubber & Chemicals Co (India)
  • Mylan N.V. (United States)
  • Chandra Bhagat Pharma Pvt. Ltd. (India)
  • Neon Laboratories Ltd (India)
  • Mayne Pharma (Australia)
  • Glaxo Smithkline Pharmaceuticals Ltd. (India)
  • Dabur Pharmaceuticals Ltd. (India)
Additional players considered in the study are as follows:
Shalaks Pharmaceuticals Pvt. Ltd. (India) , Cadila Pharmaceuticals Ltd. (India) , Samarth Pharma Pvt. Ltd. (India)
Select User Access Type

Key Highlights of Report


Jun 2019 150 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Fluorouracil (5FU) Market Report?